On May 28, 2024, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, announced that the company has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib, an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for the treatment of IDH-mutant diffuse glioma, to Royalty Pharma. Under the terms of the agreement, Agios will receive an upfront payment of $905 million upon approval of vorasidenib by the US Food and Drug Administration (FDA) and Royalty Pharma will receive the entirety of the 15% royalty on annual US net sales of vorasidenib up to $1 billion, and a 12% royalty on annual US net sales greater than $1 billion. Agios will retain a 3% royalty on annual US net sales greater than $1 billion.

The WilmerHale team advising Agios was led by George Shuster, Nathan Moore and Cynthia Mazareas and included Lauren Lifland and Matt Kosior.